Where is this company's market in its cycle, and what does that phase mean for it?
Brazil's animal health demand sits in a divided cycle, with cattle spending recovering alongside live cattle prices while hog producers operate at a loss. Poultry conditions remain reasonable, and crop-farming problems are spreading into animal health, which has made producers who also farm crops more selective about purchases.
Ourofino set aside nearly R$30 million this year for industrial facility upgrades and capacity. Revenue increased 31.3% in the first half from livestock, pet, and international sales.
Which advantages over its rivals hold up, and why are they hard to copy?
Ourofino's advantages rest on its Brazilian scale and on research and logistics built for tropical livestock, which it says let it compete with larger multinational groups. It is the third-largest animal health seller in Brazil with a reported 9% share, and it reports proximity, simpler logistics, and locally suited solutions.
Ourofino maintains its own dedicated teams in Mexico and Colombia. International operations accounted for 11% of net revenue during the first half.
What could change its growth trajectory, and what would confirm it?
Ourofino's growth now depends on widening its South American livestock footprint, where international operations supplied 11% of net revenue in the first half, and on keeping Brazilian revenue expanding faster than the industry. The company plans to enter Argentina and Uruguay and strengthen its Paraguay position by 2030. Revenue rose 31.3% in the first half to reach R$1.2 billion in 2025, up 19.5%.
Ourofino plans an annual R$80 million research budget and has allocated nearly R$30 million for facility upgrades. In Brazil it ranks as the third-largest animal health seller, holding a 9% share over the past 12 months.
What does the product do for its buyer, and how is it delivered?
Ourofino manufactures veterinary medicines and vaccines that keep cattle, horses, poultry, swine, and pets healthy, supporting food production and companion animal care. Its products cover those animal categories and are sold in Brazil and other countries. The company makes its own products, starting with Trissulfin, and also produces and sells the Ourovac Aftosa vaccine.
Colosso Pulverização is a parasite-control brand for production animals. Ourofino distributes its products through local strategic partners and serves livestock producers, veterinarians, and pet owners.
